Sai Life Sciences Expands Bidar Facility, Capacity Reaches 700 KL

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE) announced the completion of Phase II of its new Production Block (PB-11) at its API manufacturing facility in Bidar, India. With this expansion, the total installed reactor capacity at the Bidar facility reaches approximately 700 KL.

The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. The addition of Phase II (~91 KL) in Q1 FY26 brings the combined capacity of the block to approximately 200 KL, making it the single largest reactor volume block at the Bidar site.

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, stated that this expansion provides partners with the confidence to scale their needs, deliver reliably, and adapt to the increasing complexity of their programs. By strengthening large-scale API and intermediate manufacturing, the company aims to enable clients to move faster, de-risk their supply chains, and bring new medicines to market with greater assurance.

PB-11 is designed to handle large-scale commercial products. Sai Life Sciences' Unit IV in Bidar specializes in the production of APIs and advanced intermediates for highly regulated markets such as the US, EU, and Japan. Key features of the facility include:

• 12 production blocks with a combined capacity of ~700 KL
• Dedicated facilities for high-potency APIs (HPAPIs)
• State-of-the-art QC laboratories ensuring compliance and product integrity
• Advanced capabilities such as lyophilization, cryogenic reactions, high-pressure reactions, and commercial-scale chromatography

The facility has been successfully inspected and approved by leading global regulatory agencies including the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, Sai Life Sciences' manufacturing units had undergone over 75 customer audits in the past three years, reflecting its commitment to quality, safety, and compliance.

Sai Life Sciences is a leading integrated contract research, development, and manufacturing organization (CRDMO), working with over 300 global innovator pharma and biotech companies. The company has over 3,400 employees across its facilities in India, UK, and USA.

Sai Life Sciences' manufacturing units had undergone over 75 customer audits in the past three years, reflecting its commitment to quality, safety, and compliance.